ClinicalTrials.gg
CompletedNCT01511172Updated Jan 25, 2017

Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

A Phase 2 interventional study of liraglutide and metformin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 41 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-01-25.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
54th of 151
145 · median 62
Started
2002
with 1 other
Phase 2
18 of 151
2 open now
Registered
46th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 54th largest by enrollment, is one of 2 that started in 2002, is one of 18 in phase 2, and was the 46th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effect on glycemic control of NNC 90-1170 (liraglutide) added to metformin compared to metformin given alone in subjects with type 2 diabetes previously treated with OHAs (oral hypoglycaemic agents).

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 145 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with type 2 diabetes and treated with at least 50 % of maximum dose(s) of OHA(s) for at least three months
  • Duration of type 2 diabetes diagnosis at least one year
  • 8.0-13.0%, both inclusive
  • (BMI) between 25-40 kg/m\^2, both inclusive.

Exclusion criteria

Exclusion Criteria:

  • Current treatment with thiazolidinediones or insulin initiated within the last four months prior to trial
  • Impaired liver function
  • Impaired renal function
  • Cardiac problems
  • Uncontrolled treated/untreated hypertension
  • Cancer or any disease or disorder, except for conditions associated to the type 2 diabetes, which in the Investigator's opinion could interfere with the results of the trial
  • Recurrent major hypoglycaemia as judged by the Investigator
  • Known or suspected allergy to trial product or related products
  • Use of any drug (except for OHAs), which in the Investigator's opinion could interfere with the glucose level
  • Known or suspected abuse of alcohol or narcotics
  • Any to metformin or glimepiride according to the local guidelines
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    NNC 90-1170 + Met

    Drug: liraglutide · Drug: metformin

  • Experimental
    NNC 90-1170 + Met placebo

    Drug: placebo

  • Placebo comparator
    Met + NNC 90-1170 placebo

    Drug: metformin · Drug: placebo

  • Active comparator
    Met + Glim

    Drug: metformin · Drug: glimepiride

Interventions

  • Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously

  • 1000 mg daily, administered orally

  • Drugplacebo

    Metformin placebo administered orally. 1000 mg daily

  • Drugplacebo

    NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously

  • Individually adjusted dose, administered orally

07

What researchers measure

Primary outcomes

  1. Fasting plasma/serum glucose

Secondary outcomes

  1. Home monitored fasting plasma glucose

  2. Home monitored 7-point glucose profile

  3. Fructosamine

  4. Insulin

  5. C-peptide

  6. HbA1c (glycated haemoglobin A1c)

  7. Weight

  8. Beta-cell function and insulin resistance (HOMA model)

  9. Gastro-intestinal adverse events

  10. Other adverse events

08

Study locations

41 sites
  • Novo Nordisk Investigational Site
    Daw Park, South Australia 5041, Australia
  • Novo Nordisk Investigational Site
    Adelaide, SA 5035, Australia
  • Novo Nordisk Investigational Site
    Ashford, 5035, Australia
  • Novo Nordisk Investigational Site
    Garran, 2605, Australia
  • Novo Nordisk Investigational Site
    Wien, 1030, Austria
  • Novo Nordisk Investigational Site
    Wien, A 1090, Austria
  • Novo Nordisk Investigational Site
    Wien, A-1130, Austria
  • Novo Nordisk Investigational Site
    Ceske Budejovice, 37001, Czech Republic
  • Novo Nordisk Investigational Site
    Praha 10, 10034, Czech Republic
  • Novo Nordisk Investigational Site
    Frederiksberg, 2000, Denmark
  • Novo Nordisk Investigational Site
    København, 2400, Denmark
  • Novo Nordisk Investigational Site
    Køge, 4600, Denmark
  • Novo Nordisk Investigational Site
    Thisted, 7700, Denmark
  • Novo Nordisk Investigational Site
    Århus C, 8000, Denmark
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Narbonne, 11108, France
  • Novo Nordisk Investigational Site
    NEVERS cedex, 58033, France
  • Novo Nordisk Investigational Site
    Paris Cedex 10, 75475, France
  • Novo Nordisk Investigational Site
    Bad Lauterberg, 37431, Germany
  • Novo Nordisk Investigational Site
    Berlin, 12203, Germany
  • Novo Nordisk Investigational Site
    Bochum, 44791, Germany
  • Novo Nordisk Investigational Site
    Freiburg, 79106, Germany
  • Novo Nordisk Investigational Site
    Kaiserslautern, 67675, Germany
  • Novo Nordisk Investigational Site
    Mannheim, 68167, Germany
  • Novo Nordisk Investigational Site
    Neuss, 41460, Germany
  • Novo Nordisk Investigational Site
    Rawa Mazowiecka, 96-200, Poland
  • Novo Nordisk Investigational Site
    Zabrze, 41-800, Poland
  • Novo Nordisk Investigational Site
    Addlestone, KT15 2BH, United Kingdom
  • Novo Nordisk Investigational Site
    Aylesbury, HP21 7TL, United Kingdom
  • Novo Nordisk Investigational Site
    Barnsley, S70 3RJ, United Kingdom
  • Novo Nordisk Investigational Site
    Bexhill-on-Sea, TN39 4SP, United Kingdom
  • Novo Nordisk Investigational Site
    Caerleon, NP18 1AZ, United Kingdom
  • Novo Nordisk Investigational Site
    Camberley, GU15 2NN, United Kingdom
  • Novo Nordisk Investigational Site
    Chippenham, SN15 1HP, United Kingdom
  • Novo Nordisk Investigational Site
    East Horsley, KT24 6QT, United Kingdom
  • Novo Nordisk Investigational Site
    Frome, BA11 1EZ, United Kingdom
  • Novo Nordisk Investigational Site
    Magherafelt, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S3 9DA, United Kingdom
  • Novo Nordisk Investigational Site
    Soham, CB7 5JD, United Kingdom
  • Novo Nordisk Investigational Site
    Sunbury on Thames, TW16 6RH, United Kingdom
  • Novo Nordisk Investigational Site
    Yaxley. Peterborough, PE7 3JL, United Kingdom
09

References and documents

Publications

  • Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J; NN2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006 Sep;114(8):417-23. doi: 10.1055/s-2006-924230. PubMed 17039422 ↗
  • Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12. Erratum In: Diabetes Care. 2015 Aug;38(8):1622. doi: 10.2337/dc15-er08. PubMed 25504028 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002, a primary completion of Dec 2002 and a completion of Dec 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2012
First posted
Jan 18, 2012
Start
Aug 2002
Primary completionActual
Dec 2002
CompletionActual
Dec 2002
Last update
Jan 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01511172
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 18, 2012
Start date
Aug 2002
Primary completion
Dec 2002
Completion
Dec 2002
Last update
Jan 25, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liraglutide · Metformin

Start the discussion